Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EASE SBS 4: Glepaglutide Long-term Effect in Short Bowel Syndrome
NCT04991311Phase 3Completed
- Sponsor
- Zealand Pharma
- Start
- Aug 2021
- Primary completion
- Feb 2023
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of glepaglutide in short bowel syndrome (SBS), sponsored by Zealand Pharma. Primary endpoint: Change in Absorption of Wet Weight/Fluids at 24 weeks. Started Aug 2021; status: completed.
02
Drugs
glepaglutide
03
Conditions
short bowel syndrome (SBS)
Beyond the preview
Go deeper on NCT04991311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04991311.